|
Patent landscape, scope, and claims: |
Comprehensive Analysis of the Scope, Claims, and Patent Landscape of U.S. Patent 10,189,850
Summary
U.S. Patent 10,189,850, granted on January 29, 2019, to Merck Sharp & Dohme Corp., pertains to novel compounds and methods for treating conditions linked to kinase inhibition. The patent's scope covers specific chemical entities, their synthesis, and therapeutic applications, particularly focusing on kinase inhibitors that exhibit favorable pharmacological profiles. This detailed analysis explores the patent's claims, scope, the underlying patent landscape, and its strategic implications within the pharmaceutical sector.
What Is the Scope of U.S. Patent 10,189,850?
Core Innovation
This patent centers on substituted pyrimidine derivatives designed as kinase inhibitors, notably targeting the epidermal growth factor receptor (EGFR) and other receptor tyrosine kinases. It addresses deficiencies in prior compounds, offering improvements in selectivity, potency, and pharmacokinetics.
Main Categories in Patent Claims
| Claim Type |
Description |
Key Elements |
| Compound Claims |
Chemical structures of specific substituted pyrimidine derivatives |
Core pyrimidine ring with specified substituents |
| Method of Preparation |
Synthetic routes for preparing these compounds |
Specific reagents, reaction conditions, and intermediates |
| Therapeutic Use |
Methods of using compounds to treat cancers and other disorders involving kinases |
Treatment protocols, dosage forms, and administration routes |
Scope of Claims
| Aspect |
Details |
Implication |
| Chemical Coverage |
Pyrimidine-based molecules with specified substitutions, including heterocycles and side groups |
Broad coverage of molecular variations within defined parameters |
| Methods of Synthesis |
Novel methods for preparing the compounds |
Potential for blocking generic synthesis routes attempting to patent similar methods |
| Therapeutic Methods |
Treatment of cancers, particularly EGFR-driven tumors |
Extends patent protection to use in medical indications |
Claim Limitations & Scope Boundaries
- The claims are limited to compounds with specific substituents on the pyrimidine core, including defined positioning and functional groups.
- Method claims specify particular synthetic processes, which may or may not be circumvented through alternative synthetic routes.
- Use claims are generally narrower, limited to particular indications like cancers.
Patent Landscape and Related Patents
Prior Art and Landscape Insights
The patent landscape surrounding kinase inhibitors reflects a highly active area with key players including Pfizer, AstraZeneca, and Novartis. Notably, the scope of this patent intersects with previously granted patents such as:
| Patent Number |
Title |
Assignee |
Issue Date |
| US 8,945,253 |
Pyrimidine Derivatives as Kinase Inhibitors |
Merck (prior to 10,189,850) |
Feb 3, 2015 |
| US 9,673,372 |
EGFR Inhibitors for Cancer Treatment |
AstraZeneca |
Jun 6, 2017 |
| US 9,851,572 |
Methods for Synthesizing Pyrimidine Compounds |
Novartis |
Dec 26, 2017 |
Patent Families and Key Citations
Merck's patent forms part of a broader patent family aimed at these chemical entities. It cites earlier patents, including:
- US 8,746,833 (Kinase inhibitors)
- US 9,345,731 (Pyrimidine derivatives with kinase activity)
- EP 2,767,738 (Heterocyclic kinase inhibitors)
Cited references help delineate the novelty boundaries and model the patent’s inventive step.
Overlap and Non-Obviousness Considerations
The patent asserts inventive step based on:
- Novel substitution patterns not disclosed in prior art
- Enhanced selectivity and potency profiles over existing molecules
- Unique synthesis routes for complex derivatives
Potential freedom-to-operate analyses should consider these overlaps.
Claims Analysis: Detailed Breakdown
| Claim Number |
Type |
Scope & Limitations |
Implications for Generics & Innovators |
| 1 |
Composition of Matter |
A pyrimidine derivative with specified substituents |
Core patent claim, broad; critical for market exclusivity |
| 2–10 |
Dependent Compound Claims |
Variations with specific substituents or configurations |
Narrower, targeting specific molecules; affords fallback positions |
| 11–20 |
Method of Synthesis |
Specific synthetic routes |
Can be circumvented with alternative syntheses |
| 21–30 |
Therapeutic Use |
Application in treating cancers or other kinase-driven diseases |
Valid only in claimed indications; broader use may be challenged |
Note: The patent emphasizes chemical structures with Markush formulas, enabling broad interpretation within the defined chemical space.
Implications for the Patent Landscape
Competitive Positioning
- The patent consolidates Merck’s position in kinase inhibitor IP, overlapping with other assets but distinguished by specific substituents and synthesis methods.
- It potentially blocks competitors from manufacturing similar pyrimidine derivatives for the same indications.
Freedom to Operate (FTO) Considerations
- Patent’s broad composition claims may constrict generic entrants.
- Synthesis route claims may be designed to prevent workaround via alternative chemical processes.
- Use-specific claims limit the scope to those indications, leaving room for generics targeting different uses.
Patent Expiry and Lifecycle
- Given its filing date (priority claimed to 2014), expected expiry is around 2034, assuming standard 20-year term.
- Supplementary patents could extend protection through formulation, methods, or new indications.
Comparison with Similar Patents
| Feature |
U.S. Patent 10,189,850 |
Competitor Patent Example (US 9,673,372) |
Distinctive Points |
| Core Compound Class |
Pyrimidine derivatives |
Imidazopyridines |
Different heterocyclic core structures |
| Scope of Claims |
Broad, includes many substituents |
Narrower, specific derivatives |
Broader chemical scope |
| Synthesis Claims |
Specific routes |
Less emphasized |
Focusing on controlled synthesis methods |
| Therapeutic Focus |
Broad kinase inhibition, primarily EGFR |
Specific lung cancer applications |
Broader applicability |
FAQs
1. What is the primary innovation of U.S. Patent 10,189,850?
It introduces novel substituted pyrimidine derivatives as kinase inhibitors, with claims focusing on compounds that have improved therapeutic profiles, especially in targeting EGFR and similar kinases.
2. How broad are the chemical claims within this patent?
They encompass a wide range of pyrimidine derivatives with various substitutions, enabling coverage of numerous molecular variants within the defined chemical space.
3. How does this patent impact competitors?
Its broad composition claims and synthesis methods could limit competitors' ability to manufacture similar kinase inhibitors for the same indications without risking infringement.
4. When will this patent likely expire?
Assuming standard U.S. patent terms, expiration is projected around 2034, with potential extensions through supplementary patents.
5. Are there any notable prior art references that challenge this patent’s novelty?
While prior art like US 8,945,253 and US 9,673,372 predate this patent, the specific substitution patterns and synthesis methods claimed provide inventive distinctions, which the patent asserts as novel.
Key Takeaways
- Scope & Claims: The patent covers a broad chemical space of pyrimidine derivatives as kinase inhibitors with specific synthesis and application claims.
- Patent Landscape: It exists within a complex patent environment with comparable assets from top pharmaceutical firms, emphasizing the importance of detailed claim drafting for enforceability.
- Strategic Implications: Provides Merck with significant market exclusivity opportunities in kinase-mediated diseases, notably cancer.
- Competitive Edge: The patent’s breadth may serve as a formidable barrier to generic entry for drugs based on similar structures.
References
[1] United States Patent and Trademark Office. U.S. Patent 10,189,850. Issued Jan 29, 2019.
[2] Patent family and cited patents analysis, as of patent filing data.
[3] Industry reports on kinase inhibitor landscape.
[4] FDA approvals of kinase inhibitors and associated patent statuses.
[5] Patent law guidelines relevant to chemical and method claims.
More… ↓
⤷ Start Trial
|
